Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: A Danish nationwide cohort study

BMC Infectious Diseases

Volumn 11, Issue , 2011, Pages

  Hansen, Nanna ^a,h   Obel, Niels ^b   Christensen, Peer B ^c   Kjær, Mette ^b   Laursen, Alex L ^d   Krarup, Henrik B ^e   Møller, Axel ^f   Schlichting, Poul ^g   Bukh, Jens ^a   Weis, Nina ^a,h  

^a Mental Health Services CPH   (Denmark)

^b Rigshospitalet   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e AALBORG UNIVERSITY HOSPITAL   (Denmark)

^f KOLDING HOSPITAL   (Denmark)

^g GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^h UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DANISH; DRUG EFFICACY; ETHNIC GROUP; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PREDICTION; TREATMENT RESPONSE; BLOOD; DENMARK; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; STATISTICAL MODEL; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; COHORT STUDIES; DENMARK; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 79959254377     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-11-177     Document Type: Article

References (35)

1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-65. 10.1016/S0140-6736(01)06102-5, 11583749.
2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-82. 10.1056/NEJMoa020047, 12324553.
3. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM, . PEGASY International Study Group Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346-55. PEGASY International Study Group.
4. Hofmann WP, Zeuzem S. A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol 2011, Epub April 5.
5. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008, 49:634-51. 10.1016/j.jhep.2008.07.013, 18715665.
6. Foster GR, Fried MW, Hadziyannis SJ, Messinger D, Freivogel K, Weiland O. Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin. Scand J Gastroenterol 2007, 42:247-55. 10.1080/00365520600955526, 17327945.
7. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, Ibranyi E, Weiland O, Noviello S, Brass C, Albrecht J. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006, 44:97-103. 10.1016/j.jhep.2005.10.003, 16290907.
8. Dalgard O, Bjoro K, Ring-Larsen H, Bjornsson E, Holberg-Petersen M, Skovlund E, Reichard O, Myrvang B, Sundelöf B, Ritland S, Hellum K, Frydén A, Florholmen J, Verbaan H, . North-C group Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008, 47:35-42. North-C group.
9. Lagging M, Langeland N, Pedersen C, Farkkila M, Buhl MR, Morch K, Dhillon AP, Alsiö A, Hellstrand K, Westin J, Norkrans G, . NORDynamIC Study Group Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008, 47:1837-45. 10.1002/hep.22253, 18454508, NORDynamIC Study Group.
10. Elefsiniotis IS, Pavlidis C, Ketikoglou I, Koutsounas S, Scarmeas N, Pantazis KD, Moulakakis A, Tsianos EV. Patient's age modifies the impact of the proposed predictors of sustained virological response in chronic hepatitis C patients treated with PEG-interferon plus ribavirin. Eur J Intern Med 2008, 19:266-70. 10.1016/j.ejim.2007.06.014, 18471675.
11. Missiha S, Heathcote J, Arenovich T, Khan K. Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. Am J Gastroenterol 2007, 102:2181-8. 10.1111/j.1572-0241.2007.01431.x, 17640318.
12. Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007, 46:37-47.
13. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, Shafran SD, Barange K, Lin A, Soman A, Zeuzem S. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007, 357:124-34. 10.1056/NEJMoa066403, 17625124.
14. Shirakawa H, Matsumoto A, Joshita S, Komatsu M, Tanaka N, Umemura T, Ichijo T, Yoshizawa K, Kiyosawa K, Tanaka E. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 2008, 48:1753-60. 10.1002/hep.22543, 18925643.
15. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, Vinelli F, Scotto G, Bacca D, Annese M, Romano M, Zechini F, Sogari F, Spirito F, Andriulli A. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005, 352:2609-17. 10.1056/NEJMoa042608, 15972867.
16. Lagging M, Langeland N, Pedersen C, Farkkila M, Buhl MR, Morch K, Dhillon AP, Alsiö A, Hellstrand K, Westin J, Christensen P, Leutscher P, Norkrans G. Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection. Hepatology 2008, 48:695.
17. Loustaud-Ratti V, Alain S, Rousseau A, Hubert IF, Sauvage FL, Marquet P, Denis F, Lunel F, Calès P, Lefebvre A, Fauchais AL, Liozon E, Vidal E. Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology 2008, 47:1453-61. 10.1002/hep.22217, 18435468.
18. Danmarks statistik. 2008, Ref Type: Internet Communication., http://www.dst.dk
19. Hansen N, Obel N, Christensen PB, Krarup H, Laursen AL, Clausen MR, Lunding S, Møller A, Schlichting P, Kromann-Andersen H, Bukh J, Weis N. Predictors of antiviral treatment initiation in hepatitis C virus-infected patients: a Danish cohort study. J Viral Hepat 2009, 16:659-65. 10.1111/j.1365-2893.2009.01126.x, 19486467.
20. Krarup HB, Drewes AM, Madsen PH. A quantitative HCV-PCR test for routine diagnostics. Scand J Clin Lab Invest 1998, 58:415-22. 10.1080/00365519850186391, 9819190.
21. Krarup HB, Moller JM, Christensen PB, Fuglsang T, Ingerslev J, Arnfred T, Madsen PH. Haemophilic patients with hepatitis C have higher viral load compared to other well-defined patient groups. J Viral Hepat 2000, 7:435-9. 10.1046/j.1365-2893.2000.00258.x, 11115055.
22. Corbet S, Bukh J, Heinsen A, Fomsgaard A. Hepatitis C virus subtyping by a core-envelope 1-based reverse transcriptase PCR assay with sequencing and its use in determining subtype distribution among Danish patients. J Clin Microbiol 2003, 41:1091-100. 10.1128/JCM.41.3.1091-1100.2003, 150254, 12624035.
23. Laperche S, Le Marrec N, Girault A, Bouchardeau F, Servant-Delmas A, Maniez-Montreuil M, Gallian P, Levayer T, Morel P, Simon N. Simultaneous detection of hepatitis C virus (HCV) core antigen and anti-HCV antibodies improves the early detection of HCV infection. J Clin Microbiol 2005, 43:3877-83. 10.1128/JCM.43.8.3877-3883.2005, 1234013, 16081925.
24. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24:289-93. 10.1002/hep.510240201, 8690394.
25. Antonucci G, Longo MA, Angeletti C, Vairo F, Oliva A, Comandini UV, Tocci G, Boumis E, Noto P, Solmone MC, Capobianchi MR, Girardi E. The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr. Am J Gastroenterol 2007, 102:1383-91. 10.1111/j.1572-0241.2007.01201.x, 17403072.
26. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002, 36(5 Suppl 1):S47-S56.
27. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, Hashimoto E, Lefkowitch JH, Ludwig J, Okuda K. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996, 23:1334-40. 10.1002/hep.510230607, 8675148.
28. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006, 3:47-52. 1415841, 16614742.
29. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004, 39:1147-71. 10.1002/hep.20119, 15057920.
30. Wejstal R, Alaeus A, Fischler B, Reichard O, Uhnoo I, Weiland O. Chronic hepatitis C: updated Swedish consensus. Scand J Infect Dis 2003, 35:445-51. 10.1080/00365540310013252, 14514142.
31. Younossi Z, Kallman J, Kincaid J. The effects of HCV infection and management on health-related quality of life. Hepatology 2007, 45:806-16. 10.1002/hep.21565, 17326207.
32. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qui P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401. 10.1038/nature08309, 19684573.
33. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Mûller T, Bahlo M, Stewart GJ, Booth DR, George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009, 41:1100-4. 10.1038/ng.447, 19749758.
34. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009, 41:1105-9. 10.1038/ng.449, 19749757.
35. Mangia A, Thompson AJ, Santoro R, Piazolla V, Tillmann HL, Patel K, Shianna KV, Mottola L, Petruzzellis D, Bacca D, Carretta V, Minerva N, Goldstein DB, McHutchison JG. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virological response. Gastroenterology 2010, 130:821-27.